METUBINE IODIDE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jan 1949
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Metubine Iodide is an injectable small-molecule drug approved by Eli Lilly in 1949 with an unknown mechanism of action and indication profile. As a legacy NDA product nearing loss of exclusivity, its clinical role and patient population are not well-documented in modern therapeutic databases.
LOE Approaching
Approaching loss of exclusivity with minimal commercial infrastructure; limited team expansion expected and roles likely focused on lifecycle extension or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate this legacy product is a low-priority career destination at Eli Lilly. Professionals joining this product should expect limited growth trajectory, minimal team size, and focus on managed decline rather than expansion.
Brand ManagerCommercial Operations Analyst
Worked on METUBINE IODIDE at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.